You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: December 3, 2023

Investigational Drug Information for Tideglusib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Tideglusib?

Tideglusib is an investigational drug.

There have been 8 clinical trials for Tideglusib. The most recent clinical trial was a Phase 2 trial, which was initiated on August 23rd 2021.

The most common disease conditions in clinical trials are Myotonic Dystrophy, Alzheimer Disease, and Disease. The leading clinical trial sponsors are AMO Pharma Limited, Noscira SA, and Cantonal Hospital of St. Gallen.

There are twenty US patents protecting this investigational drug and one hundred and twenty-four international patents.

Recent Clinical Trials for Tideglusib
TitleSponsorPhase
Tideglusib for the Treatment of Amyotrophic Lateral SclerosisCantonal Hospital of St. GallenPhase 2
Tideglusib for the Treatment of Amyotrophic Lateral SclerosisUniversity of BernPhase 2
Tideglusib for the Treatment of Amyotrophic Lateral SclerosisUniversity of Lausanne HospitalsPhase 2

See all Tideglusib clinical trials

Clinical Trial Summary for Tideglusib

Top disease conditions for Tideglusib
Top clinical trial sponsors for Tideglusib

See all Tideglusib clinical trials

US Patents for Tideglusib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tideglusib ⤷  Try a Trial Compositions and methods for treating cancers CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) ⤷  Try a Trial
Tideglusib ⤷  Try a Trial Reprogramming fibroblasts into cardiomyocytes THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (San Francisco, CA) ⤷  Try a Trial
Tideglusib ⤷  Try a Trial Thermoreversible compositions for administration of therapeutic agents Frequency Therapeutics, Inc. (Woburn, MA) ⤷  Try a Trial
Tideglusib ⤷  Try a Trial Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders ⤷  Try a Trial
Tideglusib ⤷  Try a Trial Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) ⤷  Try a Trial
Tideglusib ⤷  Try a Trial Compositions and methods for treating cancers CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA) ⤷  Try a Trial
Tideglusib ⤷  Try a Trial Method to direct differentiation of pluripotent stem cells into functional heart muscle GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, UNIVERSITATSMEDIZIN (Gottingen, DE) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tideglusib

Drugname Country Document Number Estimated Expiration Related US Patent
Tideglusib Australia AU2015274334 2034-06-12 ⤷  Try a Trial
Tideglusib Australia AU2021201667 2034-06-12 ⤷  Try a Trial
Tideglusib Australia AU2023200895 2034-06-12 ⤷  Try a Trial
Tideglusib Canada CA2950774 2034-06-12 ⤷  Try a Trial
Tideglusib China CN106794175 2034-06-12 ⤷  Try a Trial
Tideglusib European Patent Office EP3154544 2034-06-12 ⤷  Try a Trial
Tideglusib Japan JP2017523141 2034-06-12 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Express Scripts
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.